Researchers at Vernadsky CFU develop substances for use in next-generation medicines


The team of researchers at the Department of Human and Animal Physiology and Biophysics and the Shared-Use Center of Experimental Physiology and Biophysics of Vernadsky CFU launched a preclinical study within the research project supported by the Russian Science Foundation.

According to the Project Lead, Professor Victor Shulgin, the project – titled Coordination compounds of metal bisphosphonates with spacer-armed 1,2,4-triazoles as a basis for new hybrid materials and medicines – aims to conduct bioscreening (screening for bioactivity) of  newly synthesized compounds that have the potential to become medicines.

Bisphosphonates are any of a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases.